Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma
- Determine the response rate in young patients with relapsing and/or refractory
ependymoma treated with a rapid schedule of intravenous etoposide.
- Determine the possibility of second surgery or additional radiotherapy in these
OUTLINE: This is a multicenter study.
Patients receive etoposide IV over 1 hour on days 1-3, 8-10, and 15-17. Treatment repeats
every 28 days for up to 6 courses in the absence of disease progression or unacceptable
toxicity. Patients whose tumor becomes resectable after courses 3 or 6 undergo surgical
After completion of study treatment, patients are followed periodically for approximately 5
PROJECTED ACCRUAL: At least 14 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Response rate by MRI after course 3
Linda S. Lashford
Christie Hospital NHS Foundation Trust